Saturday 17 October 2026
Export BGLC’s income statement to Excel — free account
BioNexus Gene Lab Corp.
BGLC Basic Materials Specialty Chemicals
BioNexus Gene Lab Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.4 million, down 21.9% from fiscal 2024. In the quarter to June 2026, revenue fell 96.6%, EPS grew 64.7% and free cash flow grew 44.3%, each against the same quarter a year earlier.
1.20
0.02
−1.64%
Follow BGLC
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 84.00 | 19.20 | 3.10 | 2.11 | 2.01 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 322.80 | 267.60 | 178.80 | 33.90 | 15.60 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 9 | 9 | 13 | 6 | 18 | 21 | 6 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.01 | 1.27 | 1.03 | 1.82 | 0.54 | 0.45 | 1.24 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 0 | 0 | 11 | 13 | 11 | 10 | 10 | 7 | ||||
| Gross margin, % | — | — | 13.57 | 44.02 | 15.10 | 16.96 | 11.52 | 13.61 | 13.56 | 14.62 | |||||
| EBT | — | — | 0 | 0 | 1 | 1 | 0 | (3) | (2) | (3) | |||||
| EBT margin, % | — | — | 28.21 | (217.09) | 11.08 | 7.80 | (2.78) | (26.69) | (16.77) | (40.20) | |||||
| Net income | — | — | 0 | 0 | 1 | 1 | 0 | (3) | (2) | (3) | |||||
| Depreciation | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.38 | 0.18 | 13.29 | 9.37 | 7.58 | 0.62 | 5.34 | 4.00 | ||||
| Earnings | — | — | 0.05 | (0.34) | 1.28 | 0.53 | (0.25) | (0.17) | (0.90) | (1.61) | |||||
| Cash flow | — | — | (0.50) | (0.30) | 0.64 | 0.01 | 0.38 | (0.11) | (1.17) | (0.99) | |||||
| Capex | — | — | (0.07) | (0.02) | 1.22 | 0.00 | (0.04) | (0.01) | (0.13) | (0.02) | |||||
| Free cash flow | — | — | (0.57) | (0.32) | 1.87 | 0.00 | 0.35 | (0.12) | (1.30) | (1.01) | |||||
| Book value | — | — | 2.75 | 1.56 | 7.77 | 5.03 | 4.63 | 0.61 | 4.67 | 4.64 | |||||
| Shares, m | — | — | 1 | 1 | 1 | 1 | 1 | 16 | 2 | 2 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 206.86 | 206.86 | 206.86 | 485.01 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | 19.87 | 19.87 | 19.87 | 27.28 | 15.82 | 8.48 | 0.52 | 0.99 | |||||
| P/B | — | — | 33.97 | 33.97 | 33.97 | 50.77 | 25.94 | 8.58 | 0.60 | 0.85 | |||||
| EV/Sales | — | — | 19.63 | 19.63 | 19.63 | 27.12 | 15.63 | 7.89 | 0.08 | 0.46 | |||||
| EV/FCF | — | — | 139.83 | 139.83 | 139.83 | 60,404.27 | 343.33 | (39.08) | (0.31) | (1.81) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | 0 | 0 | 1 | 0 | 1 | (2) | (2) | (2) | ||||
| Capex | — | — | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | 0 | 0 | 2 | 0 | 0 | (2) | (2) | (2) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 1 | 1 | 5 | 5 | 4 | 6 | 5 | 5 | ||||
| Total debt | — | — | 0 | 0 | 0 | 0 | 0 | — | — | — | |||||
| Net debt | — | — | (1) | (1) | (3) | (2) | (2) | (6) | (4) | (4) | |||||
| Shareholders’ equity | — | — | 2 | 1 | 7 | 7 | 7 | 10 | 8 | 9 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | 0.00 | (17.10) | 19.29 | 7.63 | (3.89) | (26.11) | (14.64) | (30.32) | ||||
| ROIC | — | — | 11.53 | (55.87) | 20.36 | 13.02 | (4.00) | (43.47) | (24.93) | (40.51) | |||||
| ROE | — | — | 0.00 | (18.64) | 28.11 | 10.86 | (5.14) | (32.21) | (17.78) | (35.24) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
BioNexus Gene Lab Corp. vs peers in Specialty Chemicals (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LOOP Loop Industries, Inc. | $18.0M | — (loss-making) | — (loss-making) | −98.34% (below 0%: shrinking) | n/m | +60.46% (above 0%: growing) | 0.00% | (1,463.69%) | Compare |
| TSEOQ Trinseo PLC | $9.5M | — (loss-making) | — (loss-making) | +7.79% (above 0%: growing) | n/m | −4,036.67% (below 0%: shrinking) | 11.79% | 0.01% | Compare |
| BON Bon Natural Life Limited | $9.2M | 0.9× | 4.5× | +20.95% (above 0%: growing) | −14.29% (below 0%: shrinking) | −260.38% (below 0%: shrinking) | 33.34% | 0.00% | Compare |
| YMAT J-Star Holding Co., Ltd | $6.1M | — | — | — | — | — | — | — | Compare |
| CRKN Crown Electrokinetics Corp. | $5.8M | — (loss-making) | 0.3× | +306.45% (above 0%: growing) | n/m | −362.52% (below 0%: shrinking) | (36.69%) | (357.14%) | Compare |
| SNES Senestech, Inc. | $3.8M | — (loss-making) | — (loss-making) | +23.20% (above 0%: growing) | n/m | −42.77% (below 0%: shrinking) | 73.64% | (241.82%) | Compare |
| BGLC BioNexus Gene Lab Corp. | $3.6M | — (loss-making) | — | −96.63% (below 0%: shrinking) | n/m | +44.32% (above 0%: growing) | 17.06% | (342.78%) | |
| CNEY CN Energy Group. Inc. | $3.3M | 2.3× | 1.1× | −99.90% (below 0%: shrinking) | +33.33% (above 0%: growing) | −113.57% (below 0%: shrinking) | 3.28% | 0.00% | Compare |
| HGAS Global Gas Corporation | $1.1M | — (loss-making) | — | — | n/m | −333.93% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $5.9M | — | 1.1× | +14.37% | — | −260.38% | 11.79% | 0.00% |
BioNexus Gene Lab Corp. (BGLC) key facts
- Concern: BioNexus Gene Lab Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.4 million, down 21.9% from fiscal 2024.
- BioNexus Gene Lab Corp. (BGLC) is a Specialty Chemicals company in the Basic Materials sector, listed on Nasdaq.
- As of October 16, 2026, BGLC traded at $1.20, a market capitalization of $3.6 million.
- Return on equity was −35.2% and debt-to-equity 0.01.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 6.34 (safe zone) for fiscal 2025.